These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
270 related items for PubMed ID: 8006330
1. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects. Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, Valenti G, Cocchi D, Müller EE, Camanni F. J Endocrinol Invest; 1994 Feb; 17(2):113-7. PubMed ID: 8006330 [Abstract] [Full Text] [Related]
2. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration. Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi M, Boffano GM, Mucci M, Boghen MF, Camanni F. J Endocrinol Invest; 1994 Mar; 17(3):157-62. PubMed ID: 8051337 [Abstract] [Full Text] [Related]
3. Low dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children. Bellone J, Bartolotta E, Cardinale G, Arvat E, Cherubini V, Aimaretti G, Maccario M, Mucci M, Camanni F, Ghigo E. J Endocrinol Invest; 1993 Mar; 16(7):521-5. PubMed ID: 8227981 [Abstract] [Full Text] [Related]
4. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E. J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341 [Abstract] [Full Text] [Related]
5. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F. J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304 [Abstract] [Full Text] [Related]
6. Effect of 15-day treatment with growth-hormone-releasing hormone alone or combined with different doses of arginine on the reduced somatotrope responsiveness to the neurohormone in normal aging. Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, Valenti G, Muller EE, Camanni F. Eur J Endocrinol; 1995 Jan; 132(1):32-6. PubMed ID: 7850007 [Abstract] [Full Text] [Related]
7. Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. Valetto MR, Bellone J, Baffoni C, Savio P, Aimaretti G, Gianotti L, Arvat E, Camanni F, Ghigo E. Eur J Endocrinol; 1996 Nov; 135(5):568-72. PubMed ID: 8980159 [Abstract] [Full Text] [Related]
8. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome. Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E. Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336 [Abstract] [Full Text] [Related]
9. Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man. Ghigo E, Miola C, Aimaretti G, Valente F, Procopio M, Arvat E, Yin-Zhang W, Camanni F. Metabolism; 1992 Sep; 41(9):1000-3. PubMed ID: 1355580 [Abstract] [Full Text] [Related]
10. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine. Procopio M, Maccario M, Grottoli S, Oleandri SE, Boffano GM, Camanni F, Ghigo E. Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266 [Abstract] [Full Text] [Related]
11. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging. Arvat E, Ceda GP, Di Vito L, Ramunni J, Gianotti L, Broglio F, Deghenghi R, Ghigo E. Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183 [Abstract] [Full Text] [Related]
12. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients. Grottoli S, Razzore P, Arvat E, Oleandri SE, Rossetto R, Ciccarelli E, Camanni F, Ghigo E. J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917 [Abstract] [Full Text] [Related]
13. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome. Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G. Dement Geriatr Cogn Disord; 1998 Nov; 9(2):78-81. PubMed ID: 9524798 [Abstract] [Full Text] [Related]
14. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects. Bellone J, Bartolotta E, Sgattoni C, Aimaretti G, Arvat E, Bellone S, Deghenghi R, Ghigo E. J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989 [Abstract] [Full Text] [Related]
20. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity. Maccario M, Procopio M, Grottoli S, Oleandri SE, Boffano GM, Taliano M, Camanni F, Ghigo E. Metabolism; 1996 Mar; 45(3):342-6. PubMed ID: 8606641 [Abstract] [Full Text] [Related] Page: [Next] [New Search]